(USA Today) – In a move that could eventually make weight loss drugs cheaper and easier to access, the Food and Drug Administration Monday approved a second generic in the category of medications known as GLP-1s.

The drugs were first approved to treat type 2 diabetes – and that’s what the FDA said daily injections of liraglutide could be used for in adults and children 10 and up. The new drug, sold under the name Victoza and made by Hikma Pharmaceuticals USA Inc., follows the approval of the generic GLP-1 exanatide last month, sold under the name Byetta. (Read More)